Release Date: 2003
Summary of Recommendations / Supporting Documents
Rating: I recommendation.
Rationale: The USPSTF found good evidence that some screening tests have good sensitivity but only fair specificity in detecting cognitive impairment and dementia. There is fair to good evidence that several drug therapies have a beneficial effect on cognitive function (equivalent to delaying the natural progression of Alzheimer's disease from 2 to 7 months), but the evidence of their beneficial effects on instrumental activities of daily living is mixed, with the benefit being small, at best. There is insufficient evidence to determine whether the benefits observed in drug trials are generalizable to patients whose disease would be detected by screening in primary care settings. The accuracy of diagnosis, the feasibility of screening and treatment in routine clinical practice, and the potential harms of screening (e.g., labeling effects) are also unknown. The Task Force therefore could not determine whether the benefits of screening for dementia outweigh the harms.Screening for Dementia, 2003
Recommendations and Rationale (PDF File, 207 KB)
Summary of the Evidence (PDF File, 289 KB)
Systematic Evidence Review (File Download; PDF Files Download)
Return to USPSTF Topic Index
USPSTF Clinical Categories
Return to USPSTF Home Page